Mice were injected with B16-OVA cells (105, intradermally), TC-1-P3(A15) (105, subcutaneously) or E.G7-OVA (5 × 105, subcutaneously) and when the tumor diameter reached 4–5 mm, they received intratumoral administration of OVA protein (0.5 mg/mouse) or EDA-HPVE7 immunogen [23 (link)] (2 nanomoles) combined with Imiquimod cream (Meda-Aldara™; topical application; 2.5 mg/mouse), poly(I:C) (Amersham; 50 μg/mouse; intratumor) or left untreated. Tumor-free mice received similar immunizations by subcutaneous route. At different time-points they were sacrificed and splenocytes, lymph node cells or tumor-infiltrating cells were obtained for characterization. Additionally, they received i.p. injection of anti-IL-10R (500 μg), anti-PD-L1 (200 μg) or the corresponding isotype control antibodies (all from BioXcell).
Anti pd l1
Manufactured by BioXCell
Sourced in United States
Anti-PD-L1 is a laboratory reagent used in scientific research. It functions as an antibody that binds to the PD-L1 protein, which is involved in regulating immune responses. This product can be used in various experimental applications to study the role of the PD-L1 pathway.
Automatically generated - may contain errors
Lab products found in correlation
Anti pd 1, by BioXCell (8 mentions)
Anti ctla4, by BioXCell (6 mentions)
Anti cd8, by BioXCell (3 mentions)
Diphtheria toxin, by Merck Group (3 mentions)
C57bl 6 mice, by Jackson ImmunoResearch (2 mentions)
Anti ox40, by BioXCell (2 mentions)
Bleomycin, by Thermo Fisher Scientific (2 mentions)
Bleomycin, by BioXCell (2 mentions)
Bleomycin, by Merck Group (2 mentions)
Rat igg2b, by BioXCell (2 mentions)
Poly 1 c, by Cytiva (1 mentions)
Anti il10r, by BioXCell (1 mentions)
Clone ltf 2, by BioXCell (1 mentions)
Anti ccl5, by R&D Systems (1 mentions)
Clone 10f 9g2, by BioXCell (1 mentions)
Matrigel, by BD (1 mentions)
Mice albumin kit, by Fortis Life Sciences (1 mentions)
Ltf 2, by BioXCell (1 mentions)
X rad 320, by Precision X-Ray (1 mentions)
Anti igg2b, by BioXCell (1 mentions)
40 protocols using anti pd l1
1
Immunotherapy in Murine Tumor Models
2
Immunotherapy Efficacy in Murine Tumor Models
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were housed in specific pathogen-free (SPF) conditions, and animal protocols were authorized by the local ethics committee. For both the subcutaneous and orthotopic tumor models, mice were treated with isotype IgG (200 μg/mouse, q3d, clone LTF-2, BioXcell), anti-PD-L1 (200 μg/mouse, q3d, clone 10F.9G2, BioXcell) or combined with anti-CCL5 (20 μg/mouse, R&D, Minneapolis, MN) intraperitoneally q3d. The anti-CD8 antibody (No. 2.43, BioXCell, UK) for eradicating CD8+ T cells was i.p. injected at a dose of 250 µg on days 6, 9, 15, and 21. Tumor volumes were measured every three days with a caliper. For the orthotopic model, C57BL/6 mice were injected with 1 × 106 Pan02-pLV-control-luc or Pan02-pLV-FOXP3-luc cells in Matrigel (BD Biosciences) into the pancreatic tail. Tumor growth was analyzed by bioluminescent imaging. The survival time of each mouse was recorded. Further information is provided in the Supplementary Materials and Methods .
3
Nephrotoxic Serum-Induced Kidney Injury
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
NTN was induced in male mice (8–12 weeks old) by intraperitoneal (i.p.) injection of 2.5 mg nephrotoxic sheep serum per gram of mouse body weight as described previously46 (link). Mice were sacrificed 8 days after NTN induction. To assess systemic antibody response, heart blood was drawn from individual mice. One day before killing, mice were housed in metabolic cages for urine collection. Albuminuria was determined by ELISA (Mice-Albumin Kit; Bethyl, Montgomery, TX). C57BL/6 mice were treated i.p. with an anti-PD-L1 antibody (250 µg/mouse; 10 F.9G2; BioXCell, West Lebanon, NH) daily starting one day after NTN induction. As isotype control, mice received rat IgG2b (250 µg/mouse; LTF-2; BioXCell). PD-L1−/− mice received i.p. an anti-IFNγ antibody (250 µg/mouse; XMG1.2; BioXCell) one day before and 4 days after NTN induction. As isotype control, rat IgG1 (1 mg/mouse; HRPN; BioXCell) was injected.
4
Radiation and Anti-PD-L1 in Tumor Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HCa-1 cells (1 × 106) were inoculated intramuscularly into the right thighs of mice, and treatment was started when the tumor reached to 8 mm in mean diameter. Four experimental groups were set; control, anti-PD-L1 alone, radiation alone, and combination of anti-PD-L1 and radiation. Mice were immobilized in specially designed mice jig and lead shield was used to avoid unwanted irradiation to other body parts. The right thighs of the mice were irradiated with 10 Gy in 1 fraction using an X-Rad 320 irradiator (Precision X-ray, North Branford, CT). Mice were treated 69 cm from the radiation source (SSD) with a dose rate of 150 cGy/min with 300 kVp X-rays, using 12.5 mA and an X-ray beam filter consisting of 2.0 mm Al. For the PD-L1 blockade experiment, anti-PD-L1 (10 mg/kg, Bio X Cell, West Lebanon, NH) was given as a total of 4 injections in 3-day intervals after radiation. For CD8+ T cell depletion experiment, anti-CD8 (12.5 mg/kg, Bio X Cell) was given in a total of 4 injections in 3-day intervals. Antibody treatment started from one day before radiation.
5
Tumor Growth Inhibition in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Wild type C57BL/6J mice (Cat: #000664) were purchased from Jackson laboratory. For tumor studies, 8 to 10-week-old mice were used. PD-L1 knockout (KO) mice were a generous gift from Dr. Lieping Chen.69 E077170 and AT-371 tumor cells were subcutaneously inoculated into the fourth mammary pad using 5 × 105 and 2x105, respectively. B16 tumor cells were subcutaneously inoculated into mouse back flank at 5 × 105. Tumor volumes were measured with calipers (0.5 × length × width2) at indicated days. Survival was determined by tumor size ≥1000 mm3 or animal death or distress. Anti-IgG2b (BioXcell, Cat: #BE0101) and anti-PD-L1 (BioXcell, Cat: #BE0090) antibodies were administered through intraperitoneal (i.p.) injection at 10 mg/kg. Anti-IgG2a (BioXcell, Cat: #BE0146) and anti-PD-1 (BioXcell, Cat: #BE0089) antibodies were administered through i.p. injection at 5 mg/kg. All antibodies were given twice per week. GW9662 (Sigma, Cat: #M6191) was intraperitoneally (i.p.) injected daily at 1 mg/kg beginning 14 days prior to tumor challenge and continuing throughout the entire tumor growth period. All animal-related procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Health Science Center at San Antonio.
6
Murine Models of Breast and Melanoma Cancers
7
Protein Expression Analysis of MDSCs and MVs
8
Paclitaxel-Loaded PLGA Nanoparticles
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Poly(lactic-co-glycolic acid) (PLGA, lactide:glycolide = 50:50, molecular weight [MW] 15,000 Da) was purchased from Jinan Daigang Biomaterial Co., Ltd. (Shandong, China). poly(vinyalcohol) (PVA, MW 25,000 Da) and polyethylenimine (PEI, MW 1800 Da) were purchased from Sigma-Aldrich (St Louis, MO, USA). Paclitaxel (PTX) was purchased from Aladdin Bio-Chem Technology Co., Ltd (Shanghai, China). Cu-tetrakis(4-carboxyphenyl)porphyrin and FITC-labeled PTX were purchased from Ruixi Biotech Co., Ltd (Xi’an, China). tLyP-1 (CGNKRTR) was synthesized by Chinapeptide (Shanghai, China). MCF-7, MCF-7/Taxol and HUVECs were purchased from the MEIXUAN Biological science and technology Co., Ltd (Shanghai, China). GSH assay kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). LysoTracker Green DND-26 and agarose were purchased from Invitrogen (Thermo Fisher Scientific). Cell Counting Kit-8 (CCK-8) Calcein-AM, and PI were obtained from Dojindo (Japan). P-gp Rabbit pAb was obtained from ABclonal (Wuhan, China). Anti-PD-L1 was purchased from BioXcell (USA). Tumor necrosis factor alpha, interferon gamma and interleukin 6 ELISA kit were purchased from Uscn Life Science, Inc., (China). Anti-CD3+-FITC, anti-CD8+a-APC and anti-CD4+-PC5.5 were purchased from Biolegend (USA). Deionized water obtained from the Millipore system (Direct-Q 5, FRA) was used in all preparations.
9
Triple Checkpoint Inhibitor Therapy
10
Tumor Regression in MUC1.Tg Mice
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!